Introduction
death, HF, hyperactivity, VT/VF, heart failure
HEART FAILURE
SCD in heart failure (HF) is the leading cause of death in the modern world. Current therapies for preventing SCD due to VT/VF are limited. For example, ICDs, the only effective therapy for VT/VF and SCD, are palliative, expensive, and pose several risks. Moreover, many patients suffer from VT/VF and SCD in the early stages of HF before they become eligible to receive an ICD (A growing body of evidence indicates that sympathetic stress-induced hyperactivity of the RyR2, located in the SR of cardiac myocytes, causes SR CaWe hypothesized that RyR2 inhibition of failing arrhythmogenic hearts reduces sarcoplasmic Ca